4.8 Article

Convergent Total Syntheses of (-)-Rubriflordilactone B and (-)-pseudo-Rubriflordilactone B

期刊

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 58, 期 50, 页码 18177-18181

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201908917

关键词

cyclotrimerization; natural products; schinortriterpenoids; structure elucidation; total synthesis

资金

  1. Marie Sklodowska-Curie actions [702385]
  2. CNU Office of the Provost
  3. EPSRC Centre for Doctoral Training in Synthesis for Biology and Medicine [EP/L015838/1]
  4. AstraZeneca
  5. Diamond Light Source
  6. Defence Science and Technology Laboratory
  7. Evotec
  8. GlaxoSmithKline
  9. Janssen
  10. Novartis
  11. Pfizer
  12. Syngenta
  13. Takeda
  14. UCB
  15. Vertex
  16. EPSRC [EP/M019195/1, EP/E055273/1]
  17. EPSRC [EP/M019195/1, EP/E055273/1] Funding Source: UKRI
  18. Marie Curie Actions (MSCA) [702385] Funding Source: Marie Curie Actions (MSCA)

向作者/读者索取更多资源

A highly convergent strategy for the synthesis of the natural product (-)-rubriflordilactone B, and the proposed structure of (-)-pseudo-rubriflordilactone B, is described. Late stage coupling of diynes containing the respective natural product FG rings with a common AB ring aldehyde precedes rhodium-catalyzed [2+2+2] alkyne cyclotrimerization to form the natural product skeleton, with the syntheses completed in just one further operation. This work resolves the uncertainty surrounding the identity of pseudo-rubriflordilactone B and provides a robust platform for further synthetic and biological investigations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据